secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K/A
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0001104659-22-060286
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium files BDSI acquisition pro forma; $669M total consideration, $75M annual synergy target
--------------------------------------------------------------------------------

- Total consideration for BDSI acquisition: $669.4M ($606.4M cash to stockholders at $5.60/share + $63.0M to retire BDSI debt).
- Pro forma combined 2021 revenue $443.6M, net income $23.5M after $132.9M in transaction-related adjustments.
- Company expects at least $75M in annual run-rate cost synergies within 12 months of closing (headcount reductions and consolidation).
- Acquisition financed via a new $650.0M term loan (modification of existing Collegium term loan); BDSI term loan paid at close.
- Preliminary purchase price allocation includes $445M in identifiable intangible assets (Belbuca, Symproic, Elyxyb) and $134M in goodwill.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465922060286/0001104659-22-060286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465922060286/tm2215301d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-060286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer